Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Argus Health
Farmers Insurance
Deloitte
UBS
US Department of Justice
Daiichi Sankyo
Merck
Chubb

Generated: November 13, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 209241

« Back to Dashboard

NDA 209241 describes INGREZZA, which is a drug marketed by Neurocrine and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the INGREZZA profile page.

The generic ingredient in INGREZZA is valbenazine tosylate. One supplier is listed for this compound. Additional details are available on the valbenazine tosylate profile page.
Summary for 209241
Tradename:INGREZZA
Applicant:Neurocrine
Ingredient:valbenazine tosylate
Patents:3
Generic Entry Opportunity Date for 209241
Generic Entry Date for 209241*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 209241
Suppliers and Packaging for NDA: 209241
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
INGREZZA valbenazine tosylate CAPSULE;ORAL 209241 NDA Neurocrine Biosciences, Inc. 70370-1040 70370-1040-1 30 CAPSULE in 1 BOTTLE (70370-1040-1)
INGREZZA valbenazine tosylate CAPSULE;ORAL 209241 NDA Neurocrine Biosciences, Inc. 70370-1040 70370-1040-2 90 CAPSULE in 1 BOTTLE (70370-1040-2)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 40MG BASE
Approval Date:Apr 11, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Apr 11, 2022
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ Try a Free TrialPatent Expiration:Oct 28, 2036Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF TARDIVE DYSKINESIA
Patent:➤ Try a Free TrialPatent Expiration:Oct 6, 2029Product Flag?YSubstance Flag?YDelist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Mallinckrodt
Moodys
AstraZeneca
Healthtrust
Deloitte
Express Scripts
Accenture
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.